Literature DB >> 28886855

Effect of Ablation for Atrial Fibrillation on Heart Failure Readmission Rates.

Parijat Saurav Joy1, Rakesh Gopinathannair2, Brian Olshansky3.   

Abstract

Atrial fibrillation (AF) and heart failure (HF) cause numerous hospital admissions. We investigated if AF increases readmissions in patients with HF and whether AF ablation alters readmissions for HF exacerbations. The 2013 Nationwide Readmissions Database was analyzed for all-cause 90-day readmissions, after discharge for HF exacerbation. Kaplan-Meier analysis was used to compare hazard rates for readmissions due to HF exacerbation, after recent ablation versus no ablation. There were 885,270 admissions for HF exacerbation of which 364,447 had coexisting AF. All-cause 90-day readmission rates were higher in patients with HF with coexisting AF versus those without AF (41.4% vs 37.6%, p <0.0001). Associated factors increasing all-cause 90-day readmissions after ablation in patients without HF were female (odds ratio [OR] 1.44, p <0.001), complication of ablation (OR 1.44, p = 0.022), coronary artery disease (OR 1.56, p <0.001), chronic lung disease (OR 1.74, p <0.001), and malnutrition (OR 10.33, p <0.001). These factors were not significant for patients with HF. HF was not a significant risk factor for complications of ablation (adjusted OR 0.82, 95% confidence interval 0.57 to 1.18). Patients who underwent ablation versus patients who were discharged after HF exacerbation without ablation had a lower rate and length of stay for the 90-day readmission episode, due to HF exacerbation (27.5% vs 41.4%, p <0.0001, and 5.58 days vs 6.60 days, p = 0.031, respectively). In conclusion, AF increased 90-day readmissions in patients with HF, and ablation for AF in patients with HF was associated with reduced frequency, length of stay, and readmissions without an increase in complication rates.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2017        PMID: 28886855     DOI: 10.1016/j.amjcard.2017.07.057

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Catheter ablation in atrial fibrillation: is there a mortality benefit in patients with diabetes and heart failure?

Authors:  M Matta; A Saglietto; P De Salvo; A Bissolino; A Ballatore; M Anselmino
Journal:  Herz       Date:  2019-05       Impact factor: 1.443

2.  Meta-analysis of randomized controlled trials on atrial fibrillation ablation in patients with heart failure with reduced ejection fraction.

Authors:  Aiman Smer; Mohsin Salih; Yousef H Darrat; Abdulghani Saadi; Raviteja Guddeti; Toufik Mahfood Haddad; Amjad Kabach; Mohamed Ayan; Alok Saurav; Hussam Abuissa; Claude S Elayi
Journal:  Clin Cardiol       Date:  2018-11-19       Impact factor: 2.882

3.  Atrioventricular Nodal Catheter Ablation in Atrial Fibrillation Complicating Congestive Heart Failure.

Authors:  Osmar Antonio Centurión; Karina Elizabeth Scavenius; Laura B García; Luis Miño; Judith Torales; Orlando Sequeira
Journal:  J Atr Fibrillation       Date:  2018-06-30

4.  Catheter ablation for atrial fibrillation is associated with reduced risk of mortality in the elderly: a prospective cohort study and propensity score analysis.

Authors:  Xin Su; Xin DU; Shang-Xin Lu; Chao Jiang; Jing DU; Shi-Jun Xia; Zhao-Jie Dong; Zhao-Xu Jia; De-Yong Long; Cai-Hua Sang; Ri-Bo Tang; Nian Liu; Song-Nan Li; Rong Bai; Jian-Zeng Dong; Chang-Sheng Ma
Journal:  J Geriatr Cardiol       Date:  2020-12-28       Impact factor: 3.327

5.  Sex Differences in the Association between Atrial Fibrillation and 90-Day Adverse Outcomes among Older Adults with Heart Failure: A Retrospective Cohort Study.

Authors:  Youn-Jung Son; Da-Young Kim; Mi Hwa Won
Journal:  Int J Environ Res Public Health       Date:  2021-02-24       Impact factor: 3.390

6.  Concomitant Atrial Fibrillation Procedures During Cardiac Surgery in a UK Center: Reflection of Worldwide Practice?

Authors:  Alina-Adriana Mistirian; Martin T Yates; Wael I Awad
Journal:  Front Cardiovasc Med       Date:  2022-03-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.